Ventured Growth with Hercules Capital · Hercules Capital

#26 – Biotech and the Public: Breakthroughs, Drug Prices, and Public Relations | Rich Aldrich

·41 min·2 clips

Rich Aldrich calls IRA pricing "negotiating with a gun pointed at your head."

1. Ventured Growth with Hercules Capital focuses on Rich Aldrich's career across Biogen, Vertex, RA Capital, and Longwood Fund, with Janice Bork guiding the conversation around biotech investing and public markets. 2. Rich Aldrich matters here as a Vertex co-founder, former chief business officer, and co-founder and partner of Longwood Fund who also helped build RA Capital. 3. The episode asks why an operator moved into investing and how public biotech, private biotech, and management teams change the investment game. 4. Rich says he left Vertex after about 12 years because he wanted less total commitment of time, less constant travel, and more control over when and where he worked. 5. He says operating experience at Biogen and Vertex helps him as an investor because he can understand what a CEO and management team are thinking in a more immersive way. 6. Rich describes launching RA Capital in 2001 after several venture firms approached him, but he thought public biotech offered better opportunities than crowded private venture capital. 7. He points to the dot-com bust and the genomic sequencing bubble burst, including the era when Solera's market cap could rise by "10 or 15 billion" on a gene discovery. 8. Rich says that collapse left public biotech companies with advanced drugs, experienced management teams, and big-pharma partnerships trading at dramatically discounted valuations. 9. He says he started RA Capital with his own money, hired Peter Kolchinsky fresh from a Harvard molecular biology PhD, and used a Fidelity retail fund and active trader platform to begin investing. 10. Rich says the initial $4 million grew quickly, then the firm restructured into a traditional limited partnership and brought in friends, family, and eventually Duke. 11. He praises Peter Kolchinsky's "Entrepreneur's Guide" and still gives it to entrepreneurs because it explains terminology and process in detail. 12. Rich says public investing taught him to build his own valuation, buy below fair value, and avoid getting emotional when market prices move. 13. He describes RA Capital's discipline of watching companies it likes, waiting for a production snag or other setback, and buying when the price hits a level they consider cheap. 14. Rich says he moved into Longwood with Christoph Westphal, Michelle Dipp, Sertris, and Concert because he wanted to work directly with management teams rather than track 20 or 30 public names. 15. He says Sertris, based on sirtuins and resveratrol science with David Sinclair, was sold to Glaxo in 2008, and Concert used deuteration chemistry to change pharmacokinetics in a way that helped create a real product. 16. Rich says Concert had strong science and leadership from Roger Tong and Nancy Stewart, but patent decisions kept it from becoming the larger company he had hoped for. 17. Rich contrasts public and private biotech by saying public companies must answer the market every day, while private companies can stay focused on R&D if they are well financed. 18. He closes on the importance of an A team, high-energy fundraisers like Josh, and the need for management teams to explain complicated science well enough to attract capital. 19. Listeners interested in biotech finance, venture investing, and drug pricing will get the most from this episode. 20. Listeners seeking product-heavy clinical science detail or a fast-paced narrative may skip it.

As heard by us

A clear look at how biotech wins, setbacks, and public judgment keep unfolding long after the science begins.

The discussion follows Rich Aldrich's path through biotech, where the real interest is not just the companies he helped start, but the way he looks back at what happened when strong science, patent choices, and market timing did or did not line up.

Read the full review in PlayNext →

Why you'd press play

For when you want a life sciences business story behind the headlines.

Read the full recommendation in PlayNext →

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from Ventured Growth with Hercules Capital